Steroid-sparing strategies in polymyalgia rheumatica: a systematic review and meta-analysis of tocilizumab with practical guidance for tapering.

BMC Rheumatol · 2026 · PMC13251128 · PMID 42035168

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Secondary outcomes Severe relapse rates The pooled estimate for severe relapse favored tocilizumab (OR: 0.57; 95% CI: 0.25–1.29; P = 0.1738; I2 = 3.8%) but did not reach statistical significance (Fig. 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.